INTRODUCTION
Central centrifugal cicatricial alopecia (CCCA) is a lymphocytic primary cicatricial alopecia that most commonly affects women of African descent, and the pathophysiology of this disease remains a mystery. 1, 2 Although a true prevalence rate has yet to be established, some studies estimate that 1 in 15 black women older than 50 years suffer from this condition. 3 Hair loss typically begins on the vertex of the scalp and gradually progresses outward centrifugally. 1, 2, 4 Although CCCA can display histologic features that overlap with those of other forms of hair loss, unlike patients with primary cicatricial alopecias, in whom appreciable inflammation is the norm, patients with CCCA can often present with minimal to seemingly absent clinical signs of inflammation on examination. 1, 5, 6 Eventually, patients develop diffuse fibrosis, which often occurs out of proportion to the clinical and histologic signs of inflammation. 1, 5 
Pathophysiology of FPDs
Fibroproliferative disorders (FPDs) is an umbrella term that encapsulates a variety of conditions characterized by aberrant wound healing and excessive fibrosis. Like CCCA, FPDs such as systemic sclerosis, keloids, atherosclerosis, and uterine fibroids (UFs) are all characterized by persistent low-grade inflammation and irritation that results in end-stage fibrosis. 7, 8 The risk of certain FPDs is increased in people of African descent, and this increased risk is thought to be secondary to the protective effect that profibrotic alleles offer against helminths found in Sub-Saharan Africa. 8, 9 In normal wound healing, injury to the skin induces a cascade of events that begins with clot formation and hemostasis. 10 The amount of collagen deposited in wounds is controlled by a delicate balance of extracellular matrix (ECM) deposition and degradation. However, in FPDs this equilibrium is disturbed, leading to excess ECM deposition and persistent fibrogenesis that occurs independently of sustained inflammation. Although there is heterogeneity of up-regulated markers between FPDs, a number of genes have been consistently implicated in the pathogenesis of FPDs. These include transforming growth factor beta gene (TGFB), platelet derived growth factor gene (PDGF ), vascular endothelial growth factor gene (VEGF ), matrix metalloproteinase matrix metalloproteinase gene 1 (MMP1), matrix metalloproteinase matrix metalloproteinase gene 2 (MMP2), matrix metalloproteinase matrix metalloproteinase gene 7 (MMP7), and matrix metalloproteinase matrix metalloproteinase gene 9 (MMP9) among others. [10] [11] [12] [13] [14] Overlap between FPDs and CCCA This process of excess fibrosis leading to permanent scar tissue formation in FPDs is similar to the process seen in CCCA, in which thick fibrous tracts replace hair follicles. 1 A recent study has shown that UFs are nearly 5 times more common in women with CCCA than in race-and sex-matched controls. 9 Given that CCCA and FPDs most commonly affect patients of African descent, coupled with the association between CCCA and a common FPD, we sought to determine the overlap in gene expression between CCCA and other FPDs.
METHODS
This study was approved by the Johns Hopkins Hospital institutional review board. Informed consent was obtained from all patients with approval from the Johns Hopkins ethics board. A total of 5 patients with biopsy-proven CCCA were recruited for this study. Two scalp biopsy specimens were obtained from each patient; 1 from CCCA-affected vertex scalp and 1 from the unaffected occipital scalp, which served as an intrascalp control. No patients had received treatment for CCCA before the skin sampling.
RNA isolation and microarray analysis
Once obtained, fresh tissue samples were immediately submerged in a 2-mL tube containing RNAlater (Qiagen, Valencia, CA) stabilization reagent. Tissue was stored at 48C for 24 hours and then transferred to a freezer for long-term storage at e808C. Total RNA was extracted by using a Qiagen RNeasy fibrous tissue kit (Qiagen, Valencia, CA). Tissue homogenization and total RNA extraction were performed according to the standard protocols. Bioanalyzer measurements of RNA quality and concentration measurements were performed before microarray analysis.
Samples were analyzed by using the Affymetrix Clariom S microarray (Affymetrix, Santa Clara, CA), which provides transcriptome-wide analysis of more than 20,000 well-annotated human genes, interrogating all known exons. The array data were imported and normalized by using the Robust Multi-Array Averaging protocol with the Partek Genomics Suite analytic platform (version 6.6, Partek, Inc., Chesterfield, MO).
Functional annotation was conducted via gene ontology, which allowed for identification of overrepresented gene function categories among upregulated or down-regulated genes to better understand the gene profile results. Special attention was paid to gene products that have been implicated in FPDs and other cicatricial alopecias.
Differential gene expression between the experimental classes was evaluated with the pairedsample 2-tailed t test algorithm to determine the transcripts' fold changes and their statistical significance, as measured by the standard deviation (SD) (from unchanged) and P values.
RESULTS
Gene expression patterns between affected scalp and intrascalp paired healthy controls were directly compared with each other. More than 21,000 genes were identified and arranged by fold change. A total of 858 genes were noted to have a fold change of more than 2 SDs. Of those, 413 were up-regulated and 445 were down-regulated in affected scalp.
Increased expression of genes that regulate fibrosis and are implicated in FPDs
The genes that were noted to be up-regulated in CCCA-affected scalp tissue include several implicated in FPDs and the regulation of fibroblast proliferation (Fig 1) . The largest group of up-regulated genes consisted of those involved in ECM organization. A total of 30 of 188 genes regulating ECM organization were noted to be up-regulated (P\.001 [ CCCA, Central centrifugal cicatricial alopecia; COL1A1, collagen type I alpha 1 chain gene; COL1A2, collagen type II alpha 1 chain gene; COL3A1, collagen type III alpha 1 chain gene; COL5A1, collagen type V alpha 1 chain gene; COL5A2, collagen type V alpha 2 chain gene; Ctrl, control; FAP, fibroblast activation protein alpha gene; FC, fold change; FN1, fibronectin 1 gene; IGF1, insulin-like growth factor 1gene; MMP1, matrix metallopeptidase 1 gene; MMP2, matrix metallopeptidase 2 gene; MMP7, matrix metallopeptidase 7 gene; MMP8, matrix metallopeptidase 8 gene; MMP9, matrix metallopeptidase 9 gene; PDGFRA, platelet derived growth factor receptor alpha gene; PDGFRB, platelet derived growth factor receptor beta gene; Pt, patient; TGFB1, transforming growth factor beta 1 gene; TGFB2, transforming growth factor beta 2 gene; VEGFA, vascular endothelial growth factor A gene; VEGFB, vascular endothelial growth factor B gene. up-regulated more than 2 SDs above the mean based on fold change. The role of MMPs in FPDs has been studied extensively. 11, 12 Although the role of MMPs is to break down ECM, certain MMPs have been implicated in FPDs such as idiopathic pulmonary fibrosis (IPF) and hepatic fibrosis. 11 In particular, MMP1, MMP2, MMP7, matrix metalloproteinase gene 8 (MMP8), and MMP9 have all been associated with increased fibrosis and are up-regulated in certain FPDs. 11, 13 Both MMP2 and MMP9 have been associated with fibrocyte migration to healing tissue, which is the source of myofibroblasts implicated in fibrosis.
11 MMP1 and MMP7 are also consistently up-regulated in IPF and have been suggested as possible biomarkers of disease.
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Of note, 6 of the 50 genes known to regulate fibroblast proliferation showed increased expression in CCCA tissue, including fibronectin 1 (FN1), platelet derived growth factor receptor alpha gene (PDGFRA), and platelet derived growth factor receptor beta gene (PDGFRB) (P = .024). FN1 and PDGF have both been implicated in the pathogenesis of FPDs. 10 PDGF plays a key role in the migration and proliferation of fibroblasts and also stimulates the recruitment of myofibroblasts, which are a key cell regulator of fibroproliferation. 11, 12 In turn, these myofibroblasts secrete fibronectin, which further encourages excess ECM deposition. Additionally, 13 of 45 genes noted to regulate endodermal cell differentiation were up-regulated in affected tissue (including several collagens, cell adhesion molecules such as integrin and laminin subunits, and MMPs) (P \ .001) Together, these genes reflect the increased collagen turnover and ECM remodeling that form a key component of sustained fibrosis seen in patients with FPDs. 10, 12, 14 Finally, 12 of 39 genes associated with organization of collagen fibril were preferentially expressed in diseased tissue (P \.001).
Decreased expression of genes regulating lipid metabolism and biosynthesis of fatty acids
The genes that were down-regulated in CCCAaffected tissue include those with roles in lipid metabolism, the hair cycle, and fatty acid biosynthesis (Table II) . In CCCA-affected scalp, 66 of 836 genes that regulate the lipid metabolic process were down-regulated (P \.001). [15] [16] [17] This includes genes such as apolipoprotein C1 gene (APOC1), apolipoprotein E gene (APOE ), ELOVL fatty acid elongase 3 gene (ELOVL3), ELOVL fatty acid elongase 3 gene (ELOVL5), fatty acid 2-hydroxylase gene (FA2H ), and stearoyl-CoA desaturase 5 gene (SCD5). Lipids play an important role in hair follicle homeostasis, and members of the SCD family have been found to play a role in maintaining sebaceous glands. 18 Transgenic mice lacking stearoyl-CoA desaturase 1 gene (SCD1) display a depletion of sebaceous lipids and alopecia and are proposed to be a model for scarring alopecia. 18 Similarly, the loss of FA2H has been linked to altered sebum composition and cyclic alopecia in the mouse model. 19 Of 34 genes that are related to the biosynthesis of unsaturated fatty acids, 7 were down-regulated in scalp tissue affected by CCCA (P \ .001). ELOVL3 was notable among these 7 genes, as ELOVL3-deficient mice have been found to exhibit a hyperplastic pilosebaceous system and a sparse hair coat. 20 Lastly, 13 of 89 genes associated with the hair cycle process, including leucine-rich repeatcontaining G protein coupled receptor 5 gene (LGR5), were down-regulated in diseased tissue.
LGR5-positive cells belong to a stem cell population that is able to generate new hair follicles and maintain hair follicle cell lineages over a long period of time. 21, 22 Additionally, loss of LGR5 has been found in the affected scalp of men with androgenetic alopecia. 22 
Ingenuity pathway analysis
We analyzed our microarray data by using Qiagen's Ingenuity Pathway Analysis (IPA) software. IPA is a robust bioinformatics search tool that utilizes the Ingenuity Knowledge Base to identify the most significant pathways within a data set. Our data showed that of all the canonic pathways analyzed with Qiagen IPA software, the greatest overlap was displayed by the hepatic fibrosis (16.5% overlap) and atherosclerosis signaling (18% overlap) pathways, both of which are PFDs (Table III) .
DISCUSSION
To our knowledge, this is the first published study of gene expression patterns in patients with CCCA. In this study, we used DNA microarrays to determine whether there is increased expression of fibroproliferative genes in patients with CCCA by comparing the expression profile of CCCA with that of other known FPDs. Through the use of IPA software, we found that our CCCA microarrays displayed the greatest overlap with hepatic fibrosis and atherosclerosis, which are 2 well-known FPDs. This discovery correlated with our findings revealing that several genes responsible for fibroblast activation, excess collagen deposition, and aberrant wound healing were up-regulated in CCCA-affected scalp compared with in unaffected scalp. A thorough review of the current literature showed a substantial overlap between the expression pattern of fibroproliferative genes in patients with CCCA and that in patients with other known FPDs (Table IV, 14,23-63 ). Of note, CCCA displayed the greatest overlap with IPF and UFs. This finding is supported by a prior study by our group in which we found that patients with CCCA are more likely to develop fibroids than their counterparts are. 9 Additionally, we noted increased expression of PDGF, COLI, COLII, COLIII, MMP1, MMP2, MMP7, and MMP9, all of which have been implicated in other FPDs. 13, 14, 23 The increased expression of these select MMPs is particularly notable. Though MMPs are typically responsible for collagen catabolism, certain MMPs are thought to induce fibrocyte migration, eventually giving rise to myofibroblasts, which are the key cell type responsible for the excess fibrosis seen in FPDs. 13 We also noted a decrease in genes that regulate lipid metabolism. Aberrant lipid metabolism has been implicated in other forms of alopecia, namely, lichen planopilaris. 64, 65 Specifically, the decreased expression of peroxisome proliferator associated receptor gamma (PPARG) is thought to incite an inflammatory response that leads to destruction of the pilosebaceous unit in primary scarring alopecias. 64, 65 Interestingly, no difference was noted in PPARG expression when CCCA-affected scalp was compared with unaffected scalp; instead, there might be adjustments of protein abundance or modification that were not tested here. This may suggest that the PPARG transcriptional changes are not a primary mediator of this phenotype of cicatricial alopecia seen in patients with CCCA.
Although there are no consensus treatments for CCCA, the mainstay of therapy remains antiinflammatory medications such as topical and intralesional steroids, and the response is often disappointing. 1, 4 However, unlike in patients with other primary cicatricial alopecias, it is not unusual for patients with CCCA to present without appreciable inflammation on the scalp, even as the disease is progressing. 1, 5, 6 Patients with early-stage CCCA, however, may exhibit a lymphocytic infiltrate on histology. 1, 4 In FPDs, though inflammation is often the inciting event that leads to fibrosis, persistent fibrogenesis occurs independent of sustained inflammation. 10, 66 This may partially explain the limited efficacy of antiinflammatory medications in FPDs. 10 We propose that a similar consideration be made in patients with CCCA. Though the cause of initial irritation to the scalp remains unclear, it may be attributed to 1 of many factors, including hair styling practices, seborrheic dermatitis, and subclinical inflammation due to androgenetic alopecia. Any one of these factors may spur long-term persistent fibrogenesis, even in the absence of continued inflammation. Although antiinflammatory therapies are helpful to some patients, they may not be sufficient to halt disease progression in all patients, as has been the experience of 2 of our authors (C.A. and L.G.). Investigation of the use of therapies targeting fibrosis in the treatment of CCCA may be warranted, as such therapies have shown some promise in other FPDs. [67] [68] [69] Our data suggest that losartan, atorvastatin, and lovastatin may be reasonable therapeutic targets that are worthy of further investigation in CCCA ( Supplemental Fig 1, A-C; available at http://www.jaad.org). However, FPDs are notoriously difficult to treat, and further research is required to identify targeted therapies for fibrosis.
This study is limited by the use of a small sample of patients and the use of whole skin tissue for analysis. Future studies may glean more information about the fibroproliferative properties of CCCA by isolating the gene expression patterns of fibroblasts in diseased scalp. Further studies are needed to establish a mechanistic pathway for the development of CCCA. Here, we have identified the upregulation of critical genes implicated in FPDs in the gene expression profile of patients with CCCA. These findings may help identify future therapeutic targets for this otherwise difficult-to-treat condition.
